Assessment of the Effect of Sub-Cutaneous Adalimumab on Prognosis of COVID-19 Patients: a Non-Randomized Pilot Clinical Trial Study in Iran.

Mehrdad Farokhnia,Mohsen Nakhaie,Sara Shafieipour, Mohammad R Z Rukerd, Mohammad M Lashkarizadeh,Abbas Pardakhty, Amirhossein Arabi, Behnam Dalfardi,Reza Sinaei, Ali Saeedpor,Bijan Ahmadi,Azam Dehghani

Clinical laboratory（2023）

引用 0|浏览4

暂无评分

摘要

This study demonstrated the efficacy of adalimumab as an alternate medication for improving SpO2, LDH, and CRP levels in COVID-19 patients.

查看译文

关键词

adalimumab, COVID-19, coronavirus, tumor necrosis factor-alpha, Iran

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要